11β-hydroxylase deficiency prevention
Jump to navigation
Jump to search
|
11β-hydroxylase deficiency Microchapters |
|
Differentiating 11β-hydroxylase deficiency from other Diseases |
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
11β-hydroxylase deficiency prevention On the Web |
|
American Roentgen Ray Society Images of 11β-hydroxylase deficiency prevention |
|
Directions to Hospitals Treating Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency |
|
Risk calculators and risk factors for 11β-hydroxylase deficiency prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mehrian Jafarizade, M.D [2]
Overview
Prenatal diagnosis of 11β-hydroxylase deficiency is conducted to prevent complication of the disease in future life and treated with prenatal dexamethasone treatment.
Primary Prevention
- Prenatal diagnosis of 11β-hydroxylase deficiency in those patients with positive family history, is conducted to prevent complication of the disease in future life and treated with prenatal dexamethasone treatment.
- The available tests are: amniotic fluid testing and oligonucleotide hybridization of deoxyribonucleic acid (DNA) obtained from chorionic villus biopsies. Utilize fetal DNA extracted from maternal blood through noninvasive methods.[1]
References
- ↑ Kazmi D, Bailey J, Yau M, Abu-Amer W, Kumar A, Low M, Yuen T (2017). "New developments in prenatal diagnosis of congenital adrenal hyperplasia". J. Steroid Biochem. Mol. Biol. 165 (Pt A): 121–123. doi:10.1016/j.jsbmb.2016.06.016. PMID 27378492.